Our Team

Nancy Bordelon, PhD, DABT

Senior Vice President, Nonclinical Development

Nancy Bordelon is the Senior Vice President of Nonclinical Development at Kriya Therapeutics. Dr. Bordelon joins Kriya from Sumitovant where she also served as Senior Vice President of Nonclinical Development. Dr. Bordelon has over 20 years of progressive leadership experience in nonclinical development for early- and late-stage investigational small molecules, biologics, and gene therapies in a variety of therapeutic indications. Dr. Bordelon has served as Head of Nonclinical Development at both Roivant and Sumitovant, where she had overall responsibility for scientific and strategic leadership for nonclinical development encompassing pharmacology, bioanalytical, and toxicology of the entire portfolio of drugs across the companies. She also served as Program Leader at Sumitovant where she spent extensive time providing cross-functional leadership for assets in development, supporting critical decision-making, managing key stakeholder relationships, and engaging with regulatory authorities. Dr. Bordelon received her PhD in toxicology from Texas A&M University and her undergraduate degree in biology from the University of Colorado.